Cerebral Microbleeds and Asundexian in Non-cardioembolic Ischemic Stroke: Secondary Analyses of the PACIFIC-STROKE Randomized Trial.

Publikation

Cerebral Microbleeds and Asundexian in Non-cardioembolic Ischemic Stroke: Secondary Analyses of the PACIFIC-STROKE Randomized Trial.

Wissenschaftlicher Artikel/Review - 10.11.2023

Balali Pargol, Hart Robert G, Smith Eric Edward, Saad Feryal, Colorado Pablo, Lemmens Robin, De Marchis Gian Marco, Caso Valeria, Xu Lizhen, Heenan Laura, Connolly Stuart J, Mundl Hardi, Shoamanesh Ashkan

Zitation

Balali P, Hart R, Smith E, Saad F, Colorado P, Lemmens R, De Marchis G, Caso V, Xu L, Heenan L, Connolly S, Mundl H, Shoamanesh A. Cerebral Microbleeds and Asundexian in Non-cardioembolic Ischemic Stroke: Secondary Analyses of the PACIFIC-STROKE Randomized Trial. Int J Stroke 2023:17474930231216339.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Int J Stroke 2023

Veröffentlichungsdatum

10.11.2023

eISSN (Online)

1747-4949

Seiten

17474930231216339

Kurzbeschreibung/Zielsetzung

Cerebral microbleeds are MRI markers of hemorrhage-prone cerebral small-vessel disease that predict future risk of ischemic stroke and intracranial hemorrhage (ICrH). There exists concerns about the net benefit of antithrombotic therapy in patients with microbleeds. We aimed to investigate the effects of an oral factor-XIa inhibitor (asundexian), that is hypothesized to inhibit thrombosis without compromising hemostasis, on the development of new microbleeds over time and interactions between microbleeds and asundexian treatment on clinical outcomes. We additionally assessed associations between baseline microbleeds and the risks of clinical and neuroimaging outcomes in patients with non-cardioembomic ischemic stroke.